Rainbow Childrens Medicare Limited (RAINBOW) — Financial Results

Investor Takeaways

Company reported audited standalone and consolidated financial results for Q4FY26 and FY26, recommending a final dividend of ₹3.50 per share (35% on ₹10 face value) subject to shareholder approval at the AGM.

Board re-appointed Dr. Ramesh Kancharla as Chairman and Managing Director for five years (August 11, 2026 – 2031) and Dr. Dinesh Kumar Chirla as Whole Time Director for a similar term.

Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati were re-appointed as Independent Directors for second terms ending in 2031.

Record date for dividend payment and AGM fixed as July 21, 2026; AGM scheduled for July 29, 2026 via VC/OVAM.

Cost Auditors Lavanya & Associates LLP re-appointed for FY 2026-27.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	Not available	Not available
Net Profit	Not available	Not available
EBITDA	Not available	Not available
EPS	₹6.76	Not available
OPM	33.75%	Not available

What Changed

Rainbow Children's Medicare released its audited financial results for the quarter and year ended March 31, 2026, alongside recommendations for a final dividend of ₹3.50 per share (35% on ₹10 face value), pending shareholder approval at the upcoming AGM. The company also announced the re-appointment of key managerial personnel, including Dr. Ramesh Kancharla as Chairman and Managing Director for a five-year term (August 11, 2026 – 2031), Dr. Dinesh Kumar Chirla as Whole Time Director for a similar term, and the re-appointment of Independent Directors Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati for second terms ending in 2031. The record date for dividend payment and AGM was fixed as July 21, 2026, with the AGM scheduled for July 29, 2026 via VC/OVAM. Cost Auditors Lavanya & Associates LLP were re-appointed for FY 2026-27. The filing confirms leadership continuity and dividend proposal but does not disclose current-period financial metrics such as revenue, net profit, or EBITDA for the reported period. The company’s market capitalization stands at ₹13,570.33 Cr with a P/E ratio of 52.22, placing it in the healthcare services sector.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Rainbow Childrens Medicare	52.22	Not available	Not available	13,570.33
Sun Pharmaceutical Industries Limited	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited	80.06	N/A	N/A	1,49,108.91

Rainbow Children's Medicare has a lower P/E ratio compared to Divi's Laboratories and Torrent Pharmaceuticals but higher than Sun Pharmaceutical Industries Limited. Its market capitalization is significantly smaller than the peers listed.